The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.

Effector Therapeutics, a US-based cancer treatment developer backed by several corporate investors, agreed to a reverse merger with special purpose acquisition company Locust Walk Acquisition Corporation today.

Locust Walk is listed on Nasdaq Capital Market under the ticker symbol LWAC having raised $175m in its January 2021 initial public offering, and the reverse merger deal will include $60m private investment in public equity (PIPE) financing and value the combined business at $419m.

The PIPE financing has been committed by investors…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn